Actively Recruiting
Urine Omics Predicting IO Therapy Responses in mRCC Patients
Led by National Taiwan University Hospital · Updated on 2022-01-20
400
Participants Needed
1
Research Sites
364 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic renal cell carcinoma.
CONDITIONS
Official Title
Urine Omics Predicting IO Therapy Responses in mRCC Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age > 20 years
- Diagnosed with advanced or metastatic renal cell carcinoma
- About to receive immuno-oncology (IO) based therapy
- ECOG performance status 0, 1, 2, or 3
- Life expectancy greater than 3 months
- Estimated glomerular filtration rate (eGFR) greater than 15 ml/min/1.73 m2
- Willing to sign the informed consent form
You will not qualify if you...
- Not willing to sign the informed consent form
- Active infection or urinary tract infection with urinary white blood cells > 5/HPF
- Other malignancies requiring active treatment (except those not needing treatment)
- Taking immune-modulating agents like corticosteroids or immune-suppressants
- Previous treatment with immuno-oncology (IO) therapy
- Received systemic anti-cancer therapies within 4 weeks before screening (except targeted therapy)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Taiwan University Hospital
Taipei, Taiwan, 100
Actively Recruiting
Research Team
Y
Yeong Shiau Pu, MD PhD
CONTACT
C
Chung Hsin Chen, MD PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here